Cytosorbents Statistics
Total Valuation
Cytosorbents has a market cap or net worth of $50.95 million. The enterprise value is $70.55 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytosorbents has 62.80 million shares outstanding. The number of shares has increased by 14.92% in one year.
| Current Share Class | 62.80M |
| Shares Outstanding | 62.80M |
| Shares Change (YoY) | +14.92% |
| Shares Change (QoQ) | -6.57% |
| Owned by Insiders (%) | 12.55% |
| Owned by Institutions (%) | 26.09% |
| Float | 54.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.32 |
| Forward PS | 1.21 |
| PB Ratio | 5.65 |
| P/TBV Ratio | 9.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.11, with a Debt / Equity ratio of 3.01.
| Current Ratio | 2.11 |
| Quick Ratio | 1.48 |
| Debt / Equity | 3.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.71 |
Financial Efficiency
Return on equity (ROE) is -93.26% and return on invested capital (ROIC) is -23.42%.
| Return on Equity (ROE) | -93.26% |
| Return on Assets (ROA) | -19.01% |
| Return on Invested Capital (ROIC) | -23.42% |
| Return on Capital Employed (ROCE) | -39.93% |
| Revenue Per Employee | $248,185 |
| Profits Per Employee | -$68,912 |
| Employee Count | 149 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 2.98 |
Taxes
| Income Tax | -2.09M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.88% in the last 52 weeks. The beta is 1.29, so Cytosorbents's price volatility has been higher than the market average.
| Beta (5Y) | 1.29 |
| 52-Week Price Change | -10.88% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 0.97 |
| Relative Strength Index (RSI) | 56.10 |
| Average Volume (20 Days) | 131,476 |
Short Selling Information
The latest short interest is 1.95 million, so 3.11% of the outstanding shares have been sold short.
| Short Interest | 1.95M |
| Short Previous Month | 1.57M |
| Short % of Shares Out | 3.11% |
| Short % of Float | 3.55% |
| Short Ratio (days to cover) | 19.01 |
Income Statement
In the last 12 months, Cytosorbents had revenue of $36.98 million and -$10.27 million in losses. Loss per share was -$0.17.
| Revenue | 36.98M |
| Gross Profit | 26.18M |
| Operating Income | -14.23M |
| Pretax Income | -12.36M |
| Net Income | -10.27M |
| EBITDA | -12.70M |
| EBIT | -14.23M |
| Loss Per Share | -$0.17 |
Full Income StatementBalance Sheet
The company has $7.54 million in cash and $27.14 million in debt, giving a net cash position of -$19.60 million or -$0.31 per share.
| Cash & Cash Equivalents | 7.54M |
| Total Debt | 27.14M |
| Net Cash | -19.60M |
| Net Cash Per Share | -$0.31 |
| Equity (Book Value) | 9.02M |
| Book Value Per Share | 0.14 |
| Working Capital | 11.20M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.89 million and capital expenditures -$125,343, giving a free cash flow of -$10.02 million.
| Operating Cash Flow | -9.89M |
| Capital Expenditures | -125,343 |
| Free Cash Flow | -10.02M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
Gross margin is 70.80%, with operating and profit margins of -38.48% and -27.77%.
| Gross Margin | 70.80% |
| Operating Margin | -38.48% |
| Pretax Margin | -33.42% |
| Profit Margin | -27.77% |
| EBITDA Margin | -34.35% |
| EBIT Margin | -38.48% |
| FCF Margin | n/a |
Dividends & Yields
Cytosorbents does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.92% |
| Shareholder Yield | -14.92% |
| Earnings Yield | -20.15% |
| FCF Yield | -19.66% |
Analyst Forecast
The average price target for Cytosorbents is $5.38, which is 563.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.38 |
| Price Target Difference | 563.22% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 40.81% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 5, 2014. It was a reverse split with a ratio of 1:25.
| Last Split Date | Dec 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Cytosorbents has an Altman Z-Score of -8.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.35 |
| Piotroski F-Score | 3 |
